Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Lisinopril Market Through 2034?
In the past few years, the lisinopril market has seen a robust expansion. The market, which was valued at $1.76 billion in 2024, is projected to reach $1.87 billion in 2025, signaling a compound annual growth rate (CAGR) of 6.4%. Key factors driving this growth during the historic period include improved accessibility, changes in lifestyle, more frequent screening programs, wider availability of generic lisinopril, and enhanced patient compliance.
The market for lisinopril is projected to experience robust growth in the upcoming years, expanding to$2.35 billion by 2029 with a compound annual growth rate (CAGR) of 5.9%. The growth anticipated in the projected period can be associated with an increasing incidence of hypertension and cardiovascular ailments, availability of generic forms and their cost benefits, improved consciousness and early detection, rising need for effective remedies, and the aging demographic. The period of prediction is expected to see significant trends such as advancements in drug delivery, the requirement for improved and patient-focused drug delivery methods, the call for cost-effective alternatives, the need for efficient treatments for heart failure, and the need for effective solutions for diabetic kidney disease.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16465&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Lisinopril Market?
The increase in cases of cardiovascular diseases is anticipated to boost the lisinopril market’s expansion. Heart and blood vessel disorders fall under the umbrella of cardiovascular diseases (CVDs). The rise in cardiovascular disease instances can be linked to several factors, including population and aging growth, risk factors, and the ineffective application of confirmed prevention and treatment approaches. Lisinopril primarily helps handle cardiovascular diseases by decreasing blood pressure and easing the pressure on the heart and kidneys. It prevents the generation of angiotensin II, encourages the expansion of blood vessels, decreases blood volume, and shields the organs from damage. For instance, Singapore Heart Foundation (SHF), a non-profit organization in Singapore, reported a slight rise in deaths due to ischemic heart disease – from 5,290 in 2022 to 5,302 in May 2024. Thus, the lisinopril market’s growth is fueled by the rising prevalence of cardiovascular diseases.
Which Key Market Segments Comprise the Lisinopril Market and Drive Its Revenue Growth?
The lisinoprilmarket covered in this report is segmented –
1) By Brand: Zestoretic; Prinivil; Zestril; Other Brands
2) By Disease: Hypertension; Heart Failure; Heart Attack; Strokes; Diabetic Kidney Disease; Other Diseases
3) By Dosage: Tablet; Liquid; Other Dosages
4) By Population Type: Children; Adults
5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Zestoretic: Different Dosage Forms; Generic Versions Of Zestoretic
2) By Prinivil: Different Dosage Forms; Generic Versions Of Prinivil
3) By Zestril: Different Dosage Forms; Generic Versions Of Zestril
4) By Other Brands: International Brand Variants; Combination Drug Formulations
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16465&type=smp
Which Areas Are Leading Regions in the Lisinopril Market Expansion Across the Globe?
North America was the largest region in the lisinopril market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
View the full report here:
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report
How Is the Lisinopril Market Conceptually Defined?
Lisinopril is a medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It functions by reducing specific chemicals that constrict blood vessels, promoting smoother blood flow and enhancing the heart’s ability to pump blood effectively. Lisinopril is prescribed to adults for the treatment of congestive heart failure and to increase survival rates following a heart attack.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16465
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model